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ABSTRACT 
We propose a structural framework for population-based cancer epidemiology and evaluate 
the performance of double-robust estimators for a binary exposure in cancer mortality. We 
performed numerical analyses to study the bias and efficiency of these estimators. 
Furthermore, we compared two different model selection strategies based on i) the Akaike 
and Bayesian Information Criteria and ii) machine-learning algorithms, and illustrated 
double-robust estimators’ performance in a real setting. In simulations with correctly 
specified models and near-positivity violations, all but the naïve estimators presented 
relatively good performance. However, the augmented inverse-probability treatment 
weighting estimator showed the largest relative bias. Under dual model misspecification and 
near-positivity violations, all double-robust estimators were biased. Nevertheless, the 
targeted maximum likelihood estimator showed the best bias-variance trade-off, more 
precise estimates, and appropriate 95% confidence interval coverage, supporting the use of 
the data-adaptive model selection strategies based on machine-learning algorithms. We 
applied these methods to estimate adjusted one-year mortality risk differences in 183,426 
lung cancer patients diagnosed after admittance to an emergency department versus non-
emergency cancer diagnosis in England, 2006-2013. The adjusted mortality risk (for patients 
diagnosed with lung cancer after admittance to an emergency department) was 16% higher 
in men and 18% higher in women, suggesting the importance of interventions targeting early 
detection of lung cancer signs and symptoms. 
 
Keywords: causality; cancer epidemiology; population-based data; statistics; machine 
learning; targeted maximum likelihood estimation 
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Data from population-based cancer registries are critical for cancer control and policy.[1-3] 
However, the scope of the information from cancer registries refers to cancer characteristics 
and basic socio-demographic factors.[1, 2, 4] Recently, linkage strategies of population-
based data sets from different sources have been implemented. This has allowed for more 
advanced modelling scenarios regarding applications in cancer policy and control.[5-10] For 
instance, comparative effectiveness approaches using medical records and linked 
population-based databases are used to evaluate the effectiveness of treatment or 
exposures concerning cancer mortality and survival.[6-10] Nevertheless, the evaluation of 
the effectiveness of treatments or exposures in a large population-based cancer 
epidemiology requires well-defined structural frameworks and modern statistical methods in 
order to overcome confounding.[9]  
The use of the Neyman-Rubin potential outcomes framework[11] allows researchers to 
make explicit the assumptions under which an observed association from observational 
studies can be interpreted causally. For a given factor to be considered causal, researchers 
must consider a set of additional assumptions (i.e., conditional exchangeability, positivity and 
consistency).[12] Directed acyclic graphs (DAGs) help to evaluate whether, under a given 
causal model, the counterfactual outcome is independent of the observed exposure given 
some sets of covariates (conditional exchangeability) selected on the basis of subject matter 
knowledge.[12-14]  
The average treatment effect (ATE) or risk difference is a commonly used parameter of 
interest.[12, 15, 16] Correct model specification is crucial to obtain unbiased estimates of the 
true ATE. Many estimators of the ATE (but not all) rely on parametric modeling assumptions, 
thereby introducing bias when the model is incorrect.[15] Researchers have developed 
double-robust estimation procedures to reduce bias due to misspecification.[17, 18] More 
recently, van der Laan has developed a targeted maximum likelihood estimation using 
machine learning algorithms to minimize the risk of model misspecification.[15, 19, 20] 
Simulations studies using targeted maximum likelihood estimation (TMLE) in finite samples 
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provide evidence of its double-robust properties and gains in performance when combined 
with machine learning algorithms.[15, 21, 22]  
However, there is no evidence evaluating the performance of TMLE compared with other 
double-robust methods in the setting of population-based cancer epidemiology. We sought 
to compare the performance of three different double-robust causal estimators of the ATE for 
cancer mortality in a simulated scenario with forced near-positivity violations (i.e., certain 
subgroups in the sample rarely or never receive treatment) and model misspecification. 
Furthermore, we studied the efficiency and bias of double-robust estimators and compared 
two different model selection strategies based on i) a combination of Akaike-Bayesian 
information criteria (AIC-BIC) and ii) machine learning algorithms and TMLE. Finally, these 
methods are illustrated with real population-based data on lung cancer patients in England. 
METHODS 
Counterfactual framework  
Based on background knowledge, we used a DAG to depict our general counterfactual 
framework (Figure 1). We considered one-year cancer mortality as a binary outcome Y and 
a generic binary exposure or treatment A, and we assumed that the following measured 
covariates were sufficient to ensure conditional exchangeability: patients’ socioeconomic 
status (W1), age (W2), cancer stage (W3), and comorbidities at diagnosis (W4) (Figure 1). 
Afterward, based on our DAG, we generated data to explore the effects of near-positivity 
violations and dual misspecification (outcome and treatment models). The set of covariates 
included in W is critical for cancer treatment decision-making.[3, 23, 24] However, cancer 
stage and patients’ comorbidities at diagnosis play a crucial role in clinical treatment choice 
and have been cited as the most important explanatory factors for cancer mortality and 
survival. [3, 23, 24] As depicted in our DAG, we highlighted the importance of patients’ 
cancer stage, socioeconomic status, and comorbidities as the minimum set needed to 
assume conditional exchangeability based on the back-door criterion. Our targeted 
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parameter was the one-year risk differences on cancer mortality for patients exposed to a 
generic exposure (A) versus non-exposed patients. 
Data generation process and Monte Carlo simulations 
We generated data based on the structural framework represented in Figure 1 by a DAG. 
The covariates (W) were drawn using a set of random uniform and binomial variables. The 
propensity score for the binary exposure (A) and the outcome variable (Y) were derived from 
a binomial logit model that included the interaction between age (W2) and comorbidities (W4) 
for the generation of Y. 
Afterward, we drew 1,000 replications from the data-generation process with sample sizes of 
1,000 and 10,000. In each replication, we estimated the binary ATE and recorded the point 
estimates and standard errors based on the influence curve in order to calculate the ATE 
standard deviations, bias, 95% confidence interval coverage and root mean squared error 
(RMSE).[25] 
Model estimation scenarios and performance evaluation 
We set two different modeling scenarios aiming to assess the performance of double-robust 
estimators of the ATE using: i) correctly specified models for the treatment and the outcome, 
and ii) misspecified models for both treatment and outcome. Correctly specified models for 
the treatment and outcome models included socioeconomic status (W1), age (W2), cancer 
stage (W3), and comorbidities (W4) as covariates. Model misspecification for the treatment 
and the outcome was forced omitting the interaction between comorbidities (W4) and age 
(W2). Data-adaptive approaches were used to estimate the treatment and outcome for 
misspecified models (Web Appendix 1 describes in more detail the model specifications for 
the data generation). For both scenarios, we included near-positivity violations that forced 
some values of the propensity score distribution close to zero. Near-positivity violations were 
evaluated visually based on the summary of the propensity score distribution. Figure 2 
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6 
illustrates the overlap of the distribution of the potential outcomes for one simulated sample 
in the first scenario (Figure 2A), and second scenario (Figure 2B).  
In the first scenario, which uses correctly specified models, we evaluated the performance of 
a classical multivariate regression adjustment with treatment (A) and covariates (W1-W4) as 
predictors of the outcome (Y), namely the naïve approach, and of three different double-
robust estimators of the ATE: i) inverse-probability treatment weighted regression-
adjustment (IPTW-RA),[26] ii) augmented inverse-probability treatment weighting (AIPTW) 
[17, 27, 28] and iii) TMLE.[15, 29] IPTW-RA is a regression model weighted by the inverse 
probability of treatment whereas AIPTW is a two-step procedure with two estimating 
equations for the treatment and mean outcome, respectively.[27]  
For the second scenario, using misspecified models, we evaluated two different data-
adaptive model selection strategies in combination with the above described double-robust 
estimators. Models for the treatment and outcome included the above-described covariates 
for the first scenario but omitted the interaction between comorbidities and age used to 
generate the data in the second scenario. (Web Appendix 1 describes in more detail the 
model specifications for the data generation.) As data-adaptive strategies, we used AIC-BIC 
approaches for the IPTW-RA and AIPTW estimators, and ensemble-learning for the TMLE 
estimator. For the IPTW-RA, we used the AIC-BIC based approach implemented in the Stata 
user-written command “bfit” (best fit).[30] The bfit algorithm sorts a set of fitted candidate 
regression models using the Akaike and Bayesian Information Criteria and displays a table 
showing the ranking of the models. Each linear predictor of the candidate models is defined 
as a linear combination of functional forms of the variables. The smallest of the candidate 
models includes only one variable. The largest of the candidate models includes all the 
variables in a fully interacted polynomial of the order prespecified by the user. We set the 
order to “2” for comparative purposes with TMLE. For simulations and analysis of the IPTW-
RA and AIPTW estimators, we used Stata v.14.1 (StataCorp, College Station, TX, U.S.) and 
the teffects ipwra and teffects aipw commands.[26] 
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7 
The TMLE estimator has not been implemented in Stata statistical software yet, so we used 
the package tmle (version 1.2.0-4) [29] from the statistical software R version 3.0.2 (R 
Foundation for Statistical Computing, Vienna, Austria). The implementation of TMLE in R 
calls the Super-Learner package. The Super-Learner uses V-fold (10-fold by default) cross-
validation to assess the performance of the prediction of the outcome and the propensity 
score models as weighted averages (ensemble-learning) of a set of machine learning 
algorithms.[29, 31] We used the default specifications of the tmle package, which included 
the following machine-learning algorithms: i) stepwise forward and backward selection; ii) 
generalized linear modeling (glm) with the covariates (W) and the treatment (A) as main 
terms; iii) a glm variant that included second order polynomials and two-by-two interactions 
of the main terms included in the model. In Web Appendix 2, we provide a basic 
implementation of the TMLE algorithm in both Stata and R statistical software as well as the 
link to a testing version of TMLE implemented in Stata. 
Monte Carlo simulation results 
First Scenario:  correctly specified models and near-positivity violation. 
The true risk difference of the ATE estimate from the 1,000 simulation repetitions was -18%. 
The naïve approach showed a biased estimate of the ATE with an overestimation of the 
treatment effect by 23% (relative bias). All double-robust estimators were nearly unbiased 
showing smaller RMSE with increasing sample size, but the TMLE presented higher 
precision (based on the difference in variances between estimators), the smallest RMSE, 
and the best coverage (95%) (Table 1, first scenario: correctly specified models).  
Second scenario: misspecification, near-positivity violation and adaptive model selection.  
The true risk difference of the ATE from the 1,000 simulation repetitions was -12%. The 
naïve approach was heavily biased, showing the highest RMSE with an underestimation of 
the treatment effect by approximately 90% (Table 1, second scenario: adaptive estimation 
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approach). The model selection strategy based on AIC-BIC did not show either bias 
reduction or coverage improvement. The double-robust TMLE estimator presented the best 
performance with more precise estimates (1% bias for a sample size of 1,000 and less than 
0.5% for a sample size of 10,000 patients)  and the highest coverage. By contrast, the 
relative bias increased with larger sample size for the AIPTW estimator using the AIC-BIC 
approach. The relative bias ranged from 1.5% (n= 1,000) to 11.7% (n= 10,000). (Table 1, 
second scenario: adaptive estimation approach) 
ILLUSTRATION 
Under the structural framework (DAG, Figure 1) described above for population-based 
cancer epidemiology, we estimated one-year adjusted mortality risk differences for cancer 
diagnosed after admittance to a hospital emergency department versus a non-emergency 
cancer diagnosis. The high proportion of lung cancer diagnosed after admittance to an 
emergency department observed in the UK (emergency presentation) has been 
hypothesized to be mainly due to multiple steps that patients undergo between the 
identification of the first symptoms and the final diagnosis by the healthcare system.  
In addition to age and socioeconomic status, we included comorbidities and cancer stage as 
confounders. Evidence shows that the presence of patient comorbidity increases the odds of 
being diagnosed with distant metastases (advanced cancer stage), and it does not lead to 
an earlier cancer diagnosis.[32] Socioeconomic status was measured using quintiles of the 
income domain of the Index of Multiple Deprivation in England,[33] comorbidities were 
measured based on the Charlson comorbidity index, [34] and stage was based on the tumor, 
node, and metastases classification of malignant tumors.[35] In England, a cancer diagnosis 
after emergency presentation correlates closely with poor one-year survival. However, the 
strength of the evidence comes from observational data and is weak, owing to 
confounding.[36] 
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9 
It is of public health interest to estimate the one-year adjusted mortality risk differences of 
cancer diagnosed after an emergency presentation, given the potential impact of a 
preventive intervention aiming to improve earlier cancer diagnosis. Quantifying the gender-
specific adjusted risk differences for one-year mortality for lung cancer patients will reinforce 
the current evidence and help to promote the policy actions required for improving early 
cancer diagnoses.  
To illustrate the estimation of the adjusted risk differences for one-year mortality, we 
extracted the data from the National Cancer Data Repository for 183,426 incident cases of 
lung cancer diagnosed between 2006 and 2013 in England, which consisted of 102,535 men 
and 80,891 women. All patients had a minimum potential follow-up of one year since the vital 
status was not assessed until December 31st, 2014. Data were restricted to cases with 
complete information on sex, age at diagnosis, comorbidities, cancer stage, socioeconomic 
deprivation, and type of cancer diagnosis. The strategy for the assessment of cancer 
diagnosis after an emergency presentation has been previously described elsewhere.[37] 
Overall, more than 80% of the patients who died within one year after a cancer diagnosis 
had been diagnosed after an emergency presentation, and only 96 (representing 0.05%) 
were lost to follow-up before one year (Web Table 1). The average age at diagnosis was 72 
years in men and 73 in women. One-year mortality after diagnosis presented a balanced 
distribution across the different age and socioeconomic groups and by quartiles of the 
Charlson comorbidity index.[34] However, stages IV and III presented with 4- and 3-fold 
higher probabilities for one-year mortality, respectively, than stage I (Table 2). 
To estimate the adjusted mortality risk difference, we used the same approaches and 
commands used for the simulation study. We provide commented code for the illustration in 
Web Appendix 2. Overall, based on double-robust estimators, we estimated that the 
adjusted risk of one-year mortality between cancer diagnosed after admittance to an 
emergency department versus non-emergency diagnosis based on double-robust estimators 
OR
IG
IN
AL
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
 
Downloaded from https://academic.oup.com/aje/article-abstract/doi/10.1093/aje/kwx317/4110407
by London School of Hygiene & Tropical Medicine user
on 14 November 2017
 
 
10 
was 16% higher in men and 18% higher in women than it was after non-emergency 
diagnosis. However, the naïve approach showed the largest risk difference with 29% and 
32% adjusted risk differences for women and men, respectively (Figure 3: 3A women; 3B 
men).  
We also used the observed covariates from the illustration to run 100 Monte Carlo 
simulations to estimate the adjusted mortality risk difference for one-year cancer mortality 
after admittance to an emergency department. Using the information on baseline covariates 
from the observed data, we simulated only the outcome and treatment models. To evaluate 
the performance of the different estimators under strong near-positivity violations, we forced 
some values of the propensity scores close to zero (Web Figure 1). However, the estimation 
models for the treatment and outcome were correctly specified during simulations to include 
the interaction between age and comorbidities (we provide the model specifications and the 
variables included for the simulations in Web Appendix 1). The propensity score distributions 
among the exposed and unexposed overlapped considerably in the real setting (Web Figure 
1A) while the overlap in the simulated scenario was poor given the strong near-positivity 
violation (Web Figure 1B). Table 3 presents the results of the simulations, which validate the 
previous results with similar findings, but with a larger sample size and fixed covariates 
coming from a real scenario, thus reproducing reality much better. TMLE presented the best 
precision and coverage and outperformed all other double-robust estimators. By contrast, 
AIPTW showed high sensitivity to the violation of the positivity assumption with a relative 
bias of 8% (Table 3). 
 
DISCUSSION 
Given the increasing availability of a different range and variety of data in population-based 
cancer epidemiology, the proposed structural framework (DAG, Figure 1) constitutes a basis 
for further development of comparative effectiveness research in population-based cancer 
OR
IG
IN
AL
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
 
Downloaded from https://academic.oup.com/aje/article-abstract/doi/10.1093/aje/kwx317/4110407
by London School of Hygiene & Tropical Medicine user
on 14 November 2017
 
 
11 
epidemiology. Developed for a binary treatment and outcome, the framework can be easily 
extended to handle time-to-event outcomes, and might be adapted to specific comparative 
effectiveness scenarios. For instance, we considered cancer patients’ comorbidities and 
stage as confounders, but it might not be the case in other comparative effectiveness 
research questions. We have recently published an article where we argue that multivariate 
adjustment for cancer-related comorbidities (those with onset date close before or after the 
date of cancer diagnosis), to evaluate the effectiveness of cancer treatment, might be 
inappropriate as it could induce collider stratification bias.[38] 
We also applied the proposed structural framework (DAG, Figure 1) to a real data scenario 
and highlighted the critical importance of considering cancer stage and patients’ 
comorbidities in the structural framework to satisfy the conditional exchangeability 
assumption in population-based cancer epidemiology. Conventional methods control for 
confounding by assuming that the effect measure of the exposure of interest is constant 
across all levels of the covariates included in the model.[39] We provided evidence of highly 
imprecise estimates of ATE in the classical naïve regression method, underestimating the 
effect of the treatment, particularly for the misspecified model in the simulation setting.  
Model misspecification with parametric modelling is always a concern in epidemiologic 
research. ATE estimators based on the propensity score or regression adjustment are 
unbiased only if estimation models are correctly specified.[17, 27, 40] Double-robust 
estimation combines these two approaches so that only one of the two models needs to be 
correctly specified to obtain an unbiased estimate of the ATE.[17, 27, 40] Previous 
simulation studies have shown that double-robust methods, including TMLE, consistently 
provide almost unbiased estimates when either the propensity score or the outcome model 
is misspecified but the other is correct.[41-43]  However, more evidence is needed to 
evaluate TMLE statistical properties under different modeling scenarios.  
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TMLE is a general algorithm that can estimate the g-formula[44] as a generalization of 
standardization defining the parameters of interest semi-parametrically as a function of the 
data-generating distribution. TMLE evaluates the target parameter (ATE) by using a double-
robust semi-parametric substitution estimation based on machine learning algorithms to 
avoid misspecification and reduce bias.[22] 
Our results showed that, when the models were correctly specified, standardization 
implemented through the IPTW-RA, AIPTW, and TMLE provided nearly unbiased estimates 
of ATE, despite near-positivity violations. TMLE, however, was the most efficient estimator. 
Nevertheless, dual misspecification is the likely scenario in population-based cancer 
epidemiology; thus, attempting to obtain the best possible estimates is paramount for policy 
recommendations. Under dual misspecification and near-positivity violations, both in 
simulations and a real-life illustration, AIPTW showed poorer performance than IPTW-RA 
and TMLE, illustrating the instability of the AIPTW to estimate values of the propensity score 
close to zero (near-positivity violations) as previously reported by Kang and Shafer.[27] 
However, basic machine-learning algorithms and ensemble-learning techniques 
implemented in the tmle and Super-Learner R-packages avoid misspecification of the 
models (either for the treatment or the outcome) used to estimate the ATE.  
To the best of our knowledge, the performance of double-robust methods using different 
model selection strategies has not been evaluated in the context of adverse estimation 
situations with a near-violations of the positivity assumption and misspecified models. Based 
on a simulated scenario, we compared the Stata user-written program bfit,[30] with machine 
and ensemble-learning algorithms implemented in the R package tmle based on the Super-
Learner.[29, 45] TMLE outperformed model selection strategies based on AIC-BIC for the 
IPTW-RA and the AIPTW estimators. By default, TMLE implementation in R sets a bounded 
distribution of the propensity score to 0.025 and 0.975, and the adaptive estimation respects 
the limits of the possible range of the targeted parameter, but AIPTW does not. So, AIPTW 
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13 
could, for instance, produce estimates that are outside the range of the targeted parameter. 
Moreover, the default AIPTW implementation in Stata will not converge for very small values 
of the propensity score with a tolerance set by default to 10-5. We had to increase the 
tolerance of the weights for the propensity score to 10-8 when using the AIC-BIC adaptive 
approach (Stata bfit) for the AIPTW estimator, given convergence problems associated with 
the near-positivity violations. The relative bias using an adaptive approach based on AIC-
BIC for the estimation of the AIPTW under difficult scenarios increases with a larger sample 
size (from 1,000 to 10,000 in our simulations setting). Hence, using AIC-BIC for the AIPTW 
estimator might not be a good option when there is a strong suspicion of model 
misspecification and near-violation of the positivity assumption. Further evidence is needed 
to evaluate our findings.  
However, AIPTW performance is similar to IPTW-RA and TMLE under certain scenarios 
(correct specification and without near-positivity violations). TMLE is computationally 
demanding, manifesting in slow run times for large cancer population data (e.g. using a 
computer with 4 cores and 16 GB of memory, the R-package tmle took 5.4 minutes to 
estimate the ATE for 10,000 patients using more advanced machine learning algorithms 
such as generalized additive models, random forests, and boosting). 
Under an adverse estimation scenario, with near-positivity violations and dual 
misspecification, the TMLE estimator of the ATE for a binary treatment and outcome 
performs better than other double-robust estimators. Its reductions in bias and gains in 
efficiency supporting the use of TMLE for a binary treatment and outcome in population-
based cancer epidemiology research. Results from the illustration provide quantitative 
evidence of an increased one-year mortality risk in patients diagnosed with lung cancer after 
attending a hospital emergency department, which should boost calls for policy interventions 
such as the implementation of the multidisciplinary diagnosis centers to improve early cancer 
diagnosis and management. 
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Figure 1. Directed acyclic graph for the proposed structural causal framework in population-
based cancer research.Conditional exchangeability of the treatment effect or exposure (A) 
on one-year cancer mortality (Y) is obtained through conditioning on a set of available 
covariates (Y1,Y0 ⊥ A|W). The minimum sufficient set, based on the back-door criterion, is 
obtained through conditioning on only W1, W3, and W4. The average treatment effect for the 
structural framework is estimated as the average risk difference between the expected effect 
of the treatment conditional on W among those treated (E(Y|A=1; W)) and the expected 
effect of the treatment conditional on W among those untreated (E(Y|A=0; W)). W: W1: 
socioeconomic status; W2: age; W3: cancer stage; W4: comorbidities 
 
Figure 2. Overlap of the propensity score for correctly specified (first scenario) and 
misspecified models (second scenario).  
 
Figure 3. Gender-specific adjusted risk difference of one-year lung cancer mortality by 
different double-robust estimators between 2006 and 2013 in England. Risk difference in 
183,426 lung cancer patients diagnosed after admittance to an emergency department 
versus non-emergency cancer diagnosis in England, 2006-2013. A: Women; B: Men; A-
IPTW: Augmented inverse-probability of treatment weighting; BF-AIPTW: Best fit augmented 
inverse-probability treatment weighting (data-adaptive estimation based on AIC-BIC); IPTW-
RA: Inverse-probability treatment weighted regression-adjustment; BF-IPTW-RA: Best fit 
inverse-probability treatment weighted regression-adjustment (data-adaptive estimation 
based on AIC-BIC); TMLE: Targeted maximum likelihood estimation (data adaptive 
estimation based on ensemble learning and k-fold cross-validation) 
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Table 1. Monte Carlo simulations (10,000) of the ATE for correctly specified models (first 
scenario) and misspecified models using adaptive approaches (second scenario) for 
different double-robust estimators. 
  ATE Absolute BIAS Relative BIAS (%) RMSE SD-ATE 95%CI coverage (%) 
First 
scenario
a
  
N=1,000 N=10,000 N=1,000 N=10,000 N=1,000 N=10,000 N=1,000 N=10,000 N=1,000 N=10,000 N=1,000 N=10,000 
 True 
ATE 
-0.1813                       
Naïve -0.2234 -0.2218 0.0421 0.0405 23.2 22.3 0.0575 0.0423 0.0391 0.0123 77 89 
AIPTW -0.1843 -0.1848 0.0030 0.0035 1.6 1.9 0.0534 0.0180 0.0533 0.0177 93 94 
IPTW-RA -0.1831 -0.1838 0.0018 0.0025 1.0 1.4 0.0500 0.0174 0.0500 0.0172 91 95 
TMLE -0.1832 -0.1821 0.0019 0.0008 1.0 0.4 0.0482 0.0158 0.0482 0.0158 95 95 
Second 
scenario
b 
 
                    
True ATE -0.1172                       
Naïve  -0.0127 -0.0121 0.1045 0.1051 89.2 89.7 0.1470 0.1100 0.1034 0.0326 0 0 
BFit 
AIPTW  
-0.1155 -0.0920 0.0017 0.0252 1.5 11.7 0.0928 0.0773 0.0928 0.0731 65 65 
BFit 
IPTW-RA  
-0.1268 -0.1192 0.0096 0.0020 8.2 1.7 0.0442 0.0305 0.0431 0.0305 52 73 
TMLE -0.1181 -0.1177 0.0009 0.0005 0.8 0.4 0.0281 0.0107 0.0281 0.0107 93 95 
a: First scenario: correctly specified models and near-positivity violation 
b: Second scenario: misspecification, near-positivity violation and adaptive model selection 
AIPTW: Augmented Inverse-Probability Treatment Weights; ATE: Average treatment effect across 1,000 simulated data sets; BFit IPTW-RA: Best 
fit based on AIC and BIC criteria inverse-Probability treatment weighted regression-adjustment; BFit AIPTW: Best fit based on AIC and BIC 
criteria augmented Inverse-Probability Treatment Weights; IPTW-RA: Inverse-Probability treatment weighted regression-adjustment; RMSE: Root 
mean square error; SD: Standard deviation; TMLE: Targeted Maximum Likelihood Estimation calling basic Super-Learner libraries (SL): SL. Step; 
SL.glm; SL.glm.interaction 
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Table 2. One-year mortality in lung cancer patients (incident cases) by stage, comorbidities, 
age, socioeconomic status, and cancer diagnosis after admittance to an emergency 
department versus non-emergency in England between 2006 and 2013, n = 183,426 (males: 
102,535; females: 80,891). 
    Mortality one year after diagnosis 
Variables Female, deaths (%) Male, deaths (%) 
Emergency presentation     
  No 53.4 59.9 
  Yes 83.7 86.4 
Stage       
  I 18.1 24.2 
  II 35.1 37.6 
  III 58.6 62.4 
  IV 82.2 85.8 
Quartiles Charlson index     
  Q1 62.8 67.6 
  Q2 64.1 68.3 
  Q3 67.2 71.4 
  Q4 72.4 75.5 
Socioeconomic Status     
  Q1 62.6 66.7 
  Q2 63.3 68.1 
  Q3 64 69.5 
  Q4 64.2 69.6 
  Q5 64.1 68.2 
Age at diagnosis (mean, sd) 73.0 (10.8) 72.6 (10.3) 
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Table 3. Monte Carlo simulation of the risk differences of one-year mortality in lung cancer 
patients (incident cases) diagnosed after admittance to an emergency department between 
2006 and 2013 in England, n = 183,426. 
Estimators ATE 
Absolute 
BIAS 
Relative 
BIAS (%) RMSE SD-ATE 
95%CI 
Coverage (%) 
 True ATE 0.1621           
AIPTW 0.1493 0.0128 7.9 0.0165 0.0104 79 
IPTW-RA 0.1587 0.0034 2.1 0.0072 0.0063 92 
TMLE 0.1620 0.0001 0.1 0.0034 0.0034 92 
 
AIPTW: Augmented Inverse-Probability Treatment Weights; ATE: Average treatment effect across 1,000 
simulated data sets; IPTW-RA: Inverse-Probability treatment weighted regression-adjustment; RMSE: Root mean 
square error; SD: Standard deviation; TMLE: Targeted Maximum Likelihood Estimation calling basic Super-
Learner libraries (SL): SL. Step; SL.glm; SL.glm.interaction 
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